EU Marketing Authorisation change for Maviret
The authorisation shortens the treatment period from from 12 to eight weeks.
Read Moreby Anna Smith | Mar 9, 2020 | News | 0
The authorisation shortens the treatment period from from 12 to eight weeks.
Read Moreby Selina McKee | Nov 14, 2017 | News | 0
The Scottish Medicines Consortium (SMC) has published new advice accepting three new medicines for use by NHS Scotland, offering patients new treatment options for soft tissue sarcoma, acromegaly and hepatitis C
Read Moreby Selina McKee | Aug 4, 2017 | News | 0
AbbVie’s hepatitis C therapy Mavyret has picked up an approval in the US just days after having been green lighted by regulators in Europe.
Read Moreby Selina McKee | Jul 31, 2017 | News | 0
Patients with hepatitis C in Europe could soon gain access to two new pan-genotypic treatment options after the European Commission issued approval for AbbVie’s Maviret and Gilead’s Vosevi following an accelerated review.
Read Moreby Selina McKee | Jun 26, 2017 | News | 0
Eight medicines have been backed for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including new therapies to treat hepatitis C, multiple sclerosis and cancer.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
